Member Info for BuenaVista

Aldebaran, is English your second language?

Me thinks the laddie doth protest too much.

Without wishing to sound like something out of the Epstein files, beware grown men carrying crayons.

A meeting organised by Collaborative Drug Discovery Inc, the company that markets CDD Vault, the data management system used by Avacta.

What they offer is Scientific Data Management: Your research data, ready when it matters. Structure without complexity.

https://www.collaborativedrug.com/

Ta

What and where was this presentation from which Stonks showed the photo?

The slide says Avacta has a database for the storage of 'bioscience' and 'ADME' for these molecules.

Bioscience is given as cytotoxicity and enzyme kinetics

ADME, stands for absorption, distribution, metabolism and elimination. Essentially pharmacokinetics.

I'm using the law of attraction on that glass of beer.🤔 Or it's using it on me.

I would appreciate it if people are making use of AI to present information, that they would state the question posed and enclose the output in [ChatGPT]...[/ChatGPT], [GROK]...[/GROK], [Gemini]...[/Gemini], etc. tags. The options for formatting text on this BB are atrocious enough as it is without the added jumble of AI and non-AI commentary.

It's actually R&D Spotlight 14. Bit of a cook up on the comms front.

For an idea of where Enhertu's costs are, run this until you get $ amounts showing: What are the costs in manufacturing Enhertu from start to finished formulation?

https://www.google.com/search?q=What+are+the+costs+in+manufacturing+Enhertu+from+start+to+finished+formulation%3F

The list price of Enhertu includes considerable sunk investment costs in research & development as well of course.

Not ten times, just over eleven times: 822 vs 74.2.

https://avacta.com/research-development-spotlight-series-episode-14/ @8:20.

Bella, do you think you could cut a cat flap in Avacta's front door so that Heathcare Royalty can come and go at leaisure?

Well I'm working on the (worst case) assumption of fund raises leading to 500m shares in issue. There are currently 437.63m. So 62.37m more shares issued, even at 50p, raises £31.15m which would be ample to see Avacta to a point where there would be a clear existential threat to big farmers' existing treatments, even without their patent cliffs.

The Power of pre|CISION® !

Yes, exactly: notice us / challenge us

Yes it is an AI-generated comparison of preclinical animal data and it augurs well, but the real proof, the clinical proof, that AVA6103 has a better efficacy profile than Enhertu will come with data in the second cohort (second because you can start to see a trend with two days points) - safety, side effects profile, pharmacokinetics, scans, and biopsies.

Yes indeed!

I've just read the RNS and, first impressions, I'm not sure whether it projects supreme confidence or smacks of desperation but it's definitely saying "Come and get us (if you can)". I'll have to give it a few more reads through..

Anyone going?

Why B2H? It would be more wonderful if EVERY FDA team felt that way.

🥴 The pub bore is a riduculous clown.

Not only has a maximum tolerated dose for doxorubicin not been found when dosing up to almost 4x the standard doxorubicin dose, which took a long, long time to prove, but now even the lifetime limit for dosing doxorubicin via faridox has been removed. All whilst showing minimal side-effects and the beginnings of excellent efficacy. That's a lot of groundwork covered by the pre|CISION trailblazer. Now, with all that experience of pre|CISION, plus indication-targetting from the Tempus AI collaboration and belief in pre|CISION amongst the clinical community, we move on to trialling THE BEAST.